Aclaris Therapeutics Publishes Presentation on ATI-052 Phase 1b Results
Aclaris Therapeutics published a presentation on Phase 1b results for ATI-052 in atopic dermatitis and asthma.
Related stories
Kvika to Host Q3 Results Presentation for Investors
Kvika banki will host a presentation of its Q3 results for investors.
M impact | EQUITY | Oct 29, 2026, 02:37 PM UTC
Nordecon Unit Signs €5.1M Contracts to Build Ukraine Warehouses
Nordecon unit Eurocon Ukraine and Airlogix signed contracts to build three warehouses in Ukraine for UAH 259.5 million, approximately €5.1 million, excluding VAT. Work is expected
L impact | EQUITY | Oct 29, 2026, 02:32 PM UTC
Basler AG shares rise 10.4% after preliminary nine-month results
Shares are on track for their best day since May, according to the alert.
M impact | EQUITY | Oct 29, 2026, 02:32 PM UTC
Rusal Agrees Bauxite, Alumina Joint Ventures in Ghana
Russia's Rusal agreed to form bauxite and alumina joint ventures to tap a large deposit in Ghana.
L impact | EQUITY | Oct 29, 2026, 02:32 PM UTC
Nordecon Unit Signs UAH 259.5 Million Warehouse Contracts
Nordecon's unit Eurocon Ukraine signed warehouse construction contracts worth UAH 259.5 million.
M impact | EQUITY | Oct 29, 2026, 02:30 PM UTC
Yubico Invites Investors to Q3 2026 Results Presentation
Yubico announced a presentation for its Q3 2026 report. The report publication date is cut off in the supplied text.
M impact | EQUITY | Oct 29, 2026, 02:30 PM UTC